PROPULSID II SETTLEMENT PROGRAM ANNOUNCEMENT
Janssen Pharmaceutica And The Plaintiffs Steering
Committee
Of The Propulsid Multi-District Litigation Announce Agreement To Resolve
Federal Cases
(February 4, 2004) -- Janssen Pharmaceutica, a Johnson & Johnson
company, and the Plaintiffs Steering Committee (PSC), through lead
counsel, Russ M. Herman of Herman, Mathis, Casey, Kitchens & Gerel, LLP,
of the PROPULSID(r) Federal Multi-District Litigation (MDL- 1355, E.D.
La.) announced today that they had reached an agreement in principle to
resolve all federal lawsuits related to the product PROPULSID (cisapride).
There are approximately 4,000 individuals included in the Federal MDL
of whom approximately 300 are alleged to have died from use of the drug.
The agreement becomes effective once 85 percent of the death claims, and
75 percent of the remainder, agree to the terms of the settlement. In
addition, 12,000 individuals who have not filed lawsuits, but whose
claims are the subject of "tolling agreements" suspending the running of
the statutes of limitations against those claims, must also agree to
participate in the settlement before it will become effective.
The agreement requires all participating plaintiffs to submit medical
records to a court appointed independent medical panel. The medical
panel will determine whether the claimed injuries were caused by
PROPULSID and otherwise meet the standards for compensation. If those
standards are met, a court-appointed special master will determine
compensatory damages. As part of the agreement, defendants will waive a
number of defenses.
Janssen will pay as compensation a minimum of $69.5 million and a
maximum of $90 million, depending upon the number of plaintiffs who
enroll in the program. Janssen will also establish an administrative
fund not to exceed $15 million, and will pay legal fees to the PSC not
to exceed $22.5 million, subject to court approval.
Please see the links below for the Settlement Program Term Sheet and
forms related to the Settlement Program.
Inquiries should be directed to Russ M. Herman of Herman, Mathis,
Casey, Kitchens & Gerel, LLP, 820 O'Keefe Avenue, New Orleans, Louisiana
70113, PH: (504) 581-4892, FAX: (504) 561-6024, for plaintiffs.
|
Press Contact: |
|
|
| |
|
|
|
Johnson & Johnson |
Jeffrey J. Leebaw |
732-524-3350 |
| |
|
|
|
Plaintiffs Steering Committee |
Russ M. Herman |
504-581-4892 |
| |
|
|
|
Investor Services |
Helen E. Short |
732-524-6491 |
| |
Stan Panasewicz |
732-524-2524 |
II. (links to)
Propulsid II
Settlement Program Term Sheet
The Court’s Consent Order
Approving Propulsid II Settlement Program
Propulsid II
Enrollment Form
Propulsid II Program Death Claim Form
– Attachment A – for Wrongful Death and Personal Injury Claims
– Attachment B – Certificate of Service for Wrongful Death Claims
Propulsid II Program Personal Injury Claim Form
– Attachment B – Certificate of Service for Personal Injury Claims
Propulsid II Medical Records Reimbursement Form - Short Form
These forms are in "PDF" format. They must be
downloaded and completed manually.